Status:

COMPLETED

Testing the Value of Smartphone Assessments of People With Mood Disorders

Lead Sponsor:

Mindstrong

Collaborating Sponsors:

Kadima Neuropsychiatry Institute

Conditions:

Major Depressive Disorder

Bipolar Disorder

Eligibility:

All Genders

18-65 years

Brief Summary

The purpose of this study is two-fold: 1. To identify the best smartphone data features (based on keyboard, sensor, voice/speech data) that correlate with mood, anxiety, and cognitive assessments in ...

Detailed Description

Progress in psychiatry will require better measurement. Currently, few clinicians use standard rating instruments for either diagnosis or outcomes. As a result, clinicians often fail to detect when a ...

Eligibility Criteria

Inclusion

  • Adult male or female aged 18 to 65 years (inclusive) at time of informed consent
  • Diagnosis of Major Depression Disorder (MDD) or Bipolar Disorder (BD) as assessed using the Structured Clinical Interview for DSM Disorders-Clinical Trials (SCID-CT)
  • Montgomery-Asberg Depression Rating Scale (MADRS) ≥ 26; Patient Health Questionnaire (PHQ-9) ≥ 15; Clinical Global Impression (CGI) ≥ 4 at screening
  • Ownership of a personal smartphone and willingness to install and maintain the Mindstrong app for digital assessments throughout participation in the study
  • Able to understand and comply with instructions in English
  • Has a significant other who accompanies participant to treatment appointments and agrees to complete assessments
  • Undergoing ketamine treatment at the Kadima Clinic, or determined by the Kadima Clinic to be eligible for ketamine treatment and agrees to receive such treatment prior to being asked to participate in this research

Exclusion

  • Female who is currently pregnant or planning a pregnancy within 6 months
  • Has any other current Axis I DSM-5 disorder other than MDD or BD, which is the primary focus of treatment
  • Has any other clinically significant medical condition or circumstance that, in the opinion of the Investigator, could affect patient safety, preclude evaluation of response, interfere with the ability to comply with study procedures, or prohibit completion of the study
  • Has a visual or physical motor impairment that could interfere with study tasks
  • Is site personnel directly affiliated with this study

Key Trial Info

Start Date :

August 8 2017

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

May 30 2019

Estimated Enrollment :

23 Patients enrolled

Trial Details

Trial ID

NCT03429361

Start Date

August 8 2017

End Date

May 30 2019

Last Update

August 22 2019

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Kadima Neuropsychiatry Institute

La Jolla, California, United States, 92037